



Contacts: Meg McGilley  
Chief Financial Officer  
(858) 480-0402

Rob Whetstone  
PondelWilkinson, Inc.  
(310) 279-5963

## Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference

**SAN DIEGO, CA – December 7, 2006** – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will participate in the panel discussion, “Satisfying the Search for Sleep,” at the RBC Capital Markets Conference at The Westin New York at Times Square hotel, on Thursday, December 14, 2006, at 12:00 p.m. Eastern Time.

A live webcast of the presentation will be available in the Investor Relations section of the company’s website under Event Scheduler at [www.somaxon.com](http://www.somaxon.com). The webcast will be archived and accessible for at least 14 days.

### **About Somaxon Pharmaceuticals**

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon’s lead product candidate, SILENOR™ (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Somaxon has completed a successful pilot Phase 2 trial for nalmefene in smoking cessation and an unsuccessful Phase 2/3 clinical trial for nalmefene for the treatment of pathological gambling, and will evaluate the results from these trials before making determinations regarding the future of the nalmefene program. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.

For more information, please visit the company’s web site at [www.somaxon.com](http://www.somaxon.com).

###